175 related articles for article (PubMed ID: 34641467)
21. Design and synthesis of novel chalcones as potent selective monoamine oxidase-B inhibitors.
Hammuda A; Shalaby R; Rovida S; Edmondson DE; Binda C; Khalil A
Eur J Med Chem; 2016 May; 114():162-9. PubMed ID: 26974383
[TBL] [Abstract][Full Text] [Related]
22. Design, economical synthesis and antiplasmodial evaluation of vanillin derived allylated chalcones and their marked synergism with artemisinin against chloroquine resistant strains of Plasmodium falciparum.
Sharma N; Mohanakrishnan D; Sharma UK; Kumar R; Richa ; Sinha AK; Sahal D
Eur J Med Chem; 2014 May; 79():350-68. PubMed ID: 24747290
[TBL] [Abstract][Full Text] [Related]
23. Anti-cancer chalcones: Structural and molecular target perspectives.
Mahapatra DK; Bharti SK; Asati V
Eur J Med Chem; 2015 Jun; 98():69-114. PubMed ID: 26005917
[TBL] [Abstract][Full Text] [Related]
24. Recent developments of chalcones as potential antibacterial agents in medicinal chemistry.
Dan W; Dai J
Eur J Med Chem; 2020 Feb; 187():111980. PubMed ID: 31877539
[TBL] [Abstract][Full Text] [Related]
25. Development of new and selective Trypanosoma cruzi trans-sialidase inhibitors from sulfonamide chalcones and their derivatives.
Kim JH; Ryu HW; Shim JH; Park KH; Withers SG
Chembiochem; 2009 Oct; 10(15):2475-9. PubMed ID: 19780074
[TBL] [Abstract][Full Text] [Related]
26. Simple chalcones and bis-chalcones ethers as possible pleiotropic agents.
Liargkova T; Hadjipavlou-Litina DJ; Koukoulitsa C; Voulgari E; Avgoustakis C
J Enzyme Inhib Med Chem; 2016; 31(2):302-13. PubMed ID: 25798685
[TBL] [Abstract][Full Text] [Related]
27. Hybrid alpha-bromoacryloylamido chalcones. Design, synthesis and biological evaluation.
Romagnoli R; Baraldi PG; Carrion MD; Cruz-Lopez O; Cara CL; Balzarini J; Hamel E; Canella A; Fabbri E; Gambari R; Basso G; Viola G
Bioorg Med Chem Lett; 2009 Apr; 19(7):2022-8. PubMed ID: 19250822
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and biological evaluation of indolyl chalcones as antitumor agents.
Kumar D; Kumar NM; Akamatsu K; Kusaka E; Harada H; Ito T
Bioorg Med Chem Lett; 2010 Jul; 20(13):3916-9. PubMed ID: 20627724
[TBL] [Abstract][Full Text] [Related]
29. Antimitotic chalcones and related compounds as inhibitors of tubulin assembly.
Ducki S
Anticancer Agents Med Chem; 2009 Mar; 9(3):336-47. PubMed ID: 19275525
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and evaluation of C3 substituted chalcone-based derivatives of 7-azaindole as protein kinase inhibitors.
Qhobosheane MA; Legoabe LJ; Josselin B; Bach S; Ruchaud S; Beteck RM
Chem Biol Drug Des; 2020 Dec; 96(6):1395-1407. PubMed ID: 32558155
[TBL] [Abstract][Full Text] [Related]
31. Synthesis of a series of novel dihydroartemisinin derivatives containing a substituted chalcone with greater cytotoxic effects in leukemia cells.
Yang X; Wang W; Tan J; Song D; Li M; Liu D; Jing Y; Zhao L
Bioorg Med Chem Lett; 2009 Aug; 19(15):4385-8. PubMed ID: 19501507
[TBL] [Abstract][Full Text] [Related]
32. Functional evaluation of synthetic flavonoids and chalcones for potential antiviral and anticancer properties.
Mateeva N; Eyunni SVK; Redda KK; Ononuju U; Hansberry TD; Aikens C; Nag A
Bioorg Med Chem Lett; 2017 Jun; 27(11):2350-2356. PubMed ID: 28442256
[TBL] [Abstract][Full Text] [Related]
33. Cytotoxic activity of substituted chalcones in terms of molecular electronic properties.
Kupcewicz B; Jarzęcki AA; Małecka M; Krajewska U; Rozalski M
Bioorg Med Chem Lett; 2014 Sep; 24(17):4260-5. PubMed ID: 25091929
[TBL] [Abstract][Full Text] [Related]
34. A Comprehensive Review of Aminochalcones.
Irfan R; Mousavi S; Alazmi M; Saleem RSZ
Molecules; 2020 Nov; 25(22):. PubMed ID: 33213087
[TBL] [Abstract][Full Text] [Related]
35. Synthesis of novel chalcones through palladium-catalyzed CO cross-coupling reaction of bromo-chalcones with ethyl acetohydroxamate and their antiplasmodial evaluation against Plasmodium falcipuram in vitro.
Reeta ; Vinoth R; Rangarajan TM; Ayushee ; Singh RP; Singh M
Bioorg Chem; 2019 May; 86():631-640. PubMed ID: 30818235
[TBL] [Abstract][Full Text] [Related]
36. Anticancer Active Heterocyclic Chalcones: Recent Developments.
Dandawate P; Ahmed K; Padhye S; Ahmad A; Biersack B
Anticancer Agents Med Chem; 2021; 21(5):558-566. PubMed ID: 32628595
[TBL] [Abstract][Full Text] [Related]
37. Synthetic chalcones and sulfonamides as new classes of Yersinia enterocolitica YopH tyrosine phosphatase inhibitors.
Martins PG; Menegatti AC; Chiaradia-Delatorre LD; de Oliveira KN; Guido RV; Andricopulo AD; Vernal J; Yunes RA; Nunes RJ; Terenzi H
Eur J Med Chem; 2013 Jun; 64():35-41. PubMed ID: 23639652
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and QSAR study of 2'-hydroxy-4'-alkoxy chalcone derivatives that exert cytotoxic activity by the mitochondrial apoptotic pathway.
Marquina S; Maldonado-Santiago M; Sánchez-Carranza JN; Antúnez-Mojica M; González-Maya L; Razo-Hernández RS; Alvarez L
Bioorg Med Chem; 2019 Jan; 27(1):43-54. PubMed ID: 30482548
[TBL] [Abstract][Full Text] [Related]
39. Advances in chalcones with anticancer activities.
Karthikeyan C; Moorthy NS; Ramasamy S; Vanam U; Manivannan E; Karunagaran D; Trivedi P
Recent Pat Anticancer Drug Discov; 2015; 10(1):97-115. PubMed ID: 25138130
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis, characterization, and anticancer activity of a novel series of O-substituted chalcone derivatives.
Ngameni B; Cedric K; Mbaveng AT; Erdoğan M; Simo I; Kuete V; Daştan A
Bioorg Med Chem Lett; 2021 Mar; 35():127827. PubMed ID: 33508467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
